Symposium 19: Insulinosensitizers: metformin and TZD

Authors

  • Luis De Loredo Córdoba Private Hospital, Córdoba, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3Sup.352

Keywords:

metformin, thiazolidinediones

Abstract

Symposium 19: Pharmacological treatment: what's new?

Insulin sensitizers: metformin and TZD

Metformin represents a striking example of a ''historical nemesis" of a drug. Today, despite the arrival of new innovative drugs, metformin still persists as a drug of first choice in type 2 diabetes mellitus (T2DM).

Multiple effects are attributed to metformin, in addition to its hypoglycemic action, weight loss, CV protection, kidney protection, beneficial action on different types of cancer, reduction of liver diseases, action on the reduction of aging, etc. It is a multifaceted drug, with multiple molecular and action mechanisms. Inhibits mitochondrial complex I, which leads to the activation of AMPK; It also decreases glucose levels through increasing GLUT4. It is one of the few oral agents that prevents weight gain or even promotes weight loss in patients with DM2 by modifying the intestinal microbiome and modulating the hypothalamic appetite regulatory centers. It also stimulates thermogenesis.

Author Biography

Luis De Loredo, Córdoba Private Hospital, Córdoba, Argentina

Diabetologist Doctor; Head of the Diabetes and Nutrition Service

References

- Ziquan LV, Yajle G. Metformin and Its Benefits for Various Diseases. Review article. Front. Endocrinol 2020; 11:191

- Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformine use is associated with reduced mortality in a diverse populaion with COVID-19 and diabetes. https://doi.org/10.1101/2020.07.29.20164020

- Lebovitz HE.1 Thiazolidinediones: the Forgotten Diabetes Medications. Current Diabetes Reports (2019) 19:151.https://doi.org/10.1007/s11892-019-1270-y.

Downloads

Published

2023-01-10

How to Cite

De Loredo, L. (2023). Symposium 19: Insulinosensitizers: metformin and TZD. Journal of the Argentine Society of Diabetes, 54(3Sup), 76–76. https://doi.org/10.47196/diab.v54i3Sup.352

Issue

Vol. 54 No. 3Sup (2020): September/December 2020

Section

Symposiums part 5

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)